Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Multiple Myeloma | Research article

Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway

Authors: Wenfeng He, Yonghui Fu, Yongliang Zheng, Xiaoping Wang, Bin Liu, Junquan Zeng

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Side population (SP) cells, which have similar features to those of cancer stem cells, show resistance to dexamethasone (Dex) treatment. Thus, new drugs that can be used in combination with Dex to reduce the population of SP cells in multiple myeloma (MM) are required. Diallyl thiosulfinate (DATS, allicin), a natural organosulfur compound derived from garlic, has been shown to inhibit the proliferation of SP cells in MM cell lines. Therefore, we investigated the effect of a combination of DATS and Dex (DAT + Dex) on MM SP cells.

Methods

SP cells were sorted from MM RPMI-8226 and NCI-H929 cell lines using Hoechst 33342-labeled fluorescence-activated cell sorting. The growth of SP cells was evaluated using the cell counting kit-8 assay. Cell cycle and apoptosis assays were conducted using a BD Calibur flow cytometer. miRNA expression was measured using quantitative reverse transcription-polymerase chain reaction. Phosphoinositide 3-kinase (PI3K), phosphorylated AKT (p-AKT), AKT, p-mechanistic target of rapamycin (mTOR), and mTOR levels were measured using western blot analysis.

Results

Our results showed that the combination of DATS+Dex inhibited sphere formation, colony formation, and proliferation of MM SP cells by inducing apoptosis and cell cycle arrest in the G1/S phase. In addition, the combination of DATS+Dex promoted miR-127-3p expression and inhibited PI3K, p-AKT, and p-mTOR expression in SP cells. Knockdown of miR-127-3p expression weakened the effect of DATS+Dex on cell proliferation, colony formation, apoptosis, and cell cycle of MM SP cells. Additionally, knockdown of miR-127-3p activated the PI3K/AKT/mTOR signaling pathway in MM SP cells cotreated with DATS+Dex.

Conclusion

We demonstrated that cotreatment with DATS+Dex reduced cell proliferation, promoted apoptosis, and caused cell cycle arrest of MM SP cells by promoting miR-127-3p expression and deactivating the PI3K/AKT/mTOR signaling pathway.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5–11.CrossRef Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5–11.CrossRef
2.
go back to reference Fayaz SM, Suvanish Kumar VS, Rajanikant GK. Necroptosis: who knew there were so many interesting ways to die? CNS Neurol Disord Drug Targets. 2014;13(1):42–51.CrossRef Fayaz SM, Suvanish Kumar VS, Rajanikant GK. Necroptosis: who knew there were so many interesting ways to die? CNS Neurol Disord Drug Targets. 2014;13(1):42–51.CrossRef
3.
go back to reference Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797–806.CrossRef Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797–806.CrossRef
4.
go back to reference Wang L. Li Y: [research advances of side population cells in multiple myeloma -review]. Zhongguo shi yan xue ye xue za zhi. 2017;25(4):1250–4.PubMed Wang L. Li Y: [research advances of side population cells in multiple myeloma -review]. Zhongguo shi yan xue ye xue za zhi. 2017;25(4):1250–4.PubMed
5.
go back to reference Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.CrossRef Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.CrossRef
6.
go back to reference Yan W, Du J, Du Y, Pu H, Liu S, He J, Zhang J, Hou J. Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen. Leuk Res. 2016;51:32–40.CrossRef Yan W, Du J, Du Y, Pu H, Liu S, He J, Zhang J, Hou J. Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen. Leuk Res. 2016;51:32–40.CrossRef
7.
go back to reference Mikaili P, Maadirad S, Moloudizargari M, Aghajanshakeri S, Sarahroodi S. Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. Iran J Basic Med Sci. 2013;16(10):1031–48.PubMedPubMedCentral Mikaili P, Maadirad S, Moloudizargari M, Aghajanshakeri S, Sarahroodi S. Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. Iran J Basic Med Sci. 2013;16(10):1031–48.PubMedPubMedCentral
8.
go back to reference Lai KC, Hsu SC, Yang JS, Yu CC, Lein JC, Chung JG. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth. J Cell Mol Med. 2015;19(2):474–84.CrossRef Lai KC, Hsu SC, Yang JS, Yu CC, Lein JC, Chung JG. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth. J Cell Mol Med. 2015;19(2):474–84.CrossRef
9.
go back to reference Zeng JQ, Zheng YL, Liu B, Lian JP, Gong ZN. Mechanism of DATS inhibiting side population cell proliferation in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(4):1086–91.PubMed Zeng JQ, Zheng YL, Liu B, Lian JP, Gong ZN. Mechanism of DATS inhibiting side population cell proliferation in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(4):1086–91.PubMed
10.
go back to reference Wang H, Sun N, Li X, Li K, Tian J, Li J. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway. Oncol Rep. 2016;35(6):3648–58.CrossRef Wang H, Sun N, Li X, Li K, Tian J, Li J. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway. Oncol Rep. 2016;35(6):3648–58.CrossRef
11.
go back to reference Shin DY, Kim GY, Hwang HJ, Kim WJ, Choi YH. Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K/Akt and JNK pathways. Environ Toxicol Pharmacol. 2014;37(1):74–83.CrossRef Shin DY, Kim GY, Hwang HJ, Kim WJ, Choi YH. Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K/Akt and JNK pathways. Environ Toxicol Pharmacol. 2014;37(1):74–83.CrossRef
12.
go back to reference Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al. Pro-apoptotic and pro-autophagic effects of the Aurora kinase a inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Drug Design Dev Therapy. 2015;9:1555–84. Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al. Pro-apoptotic and pro-autophagic effects of the Aurora kinase a inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Drug Design Dev Therapy. 2015;9:1555–84.
13.
go back to reference Xu P, Xia T, Ling Y, Chen B. MiRNAs with prognostic significance in multiple myeloma: a systemic review and meta-analysis. Medicine. 2019;98(33):e16711.CrossRef Xu P, Xia T, Ling Y, Chen B. MiRNAs with prognostic significance in multiple myeloma: a systemic review and meta-analysis. Medicine. 2019;98(33):e16711.CrossRef
14.
go back to reference Huang YH, Chen ST, Liu FH, Hsieh SH, Lin CH, Liou MJ, Wang CC, Huang CH, Liu GH, Lin JR, et al. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: a randomized, double-blind, placebo-controlled pilot trial. PLoS One. 2019;14(8):e0221199.CrossRef Huang YH, Chen ST, Liu FH, Hsieh SH, Lin CH, Liou MJ, Wang CC, Huang CH, Liu GH, Lin JR, et al. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: a randomized, double-blind, placebo-controlled pilot trial. PLoS One. 2019;14(8):e0221199.CrossRef
15.
go back to reference Wu H, Liu C, Yang Q, Xin C, Du J, Sun F, Zhou L. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683–97.CrossRef Wu H, Liu C, Yang Q, Xin C, Du J, Sun F, Zhou L. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683–97.CrossRef
16.
go back to reference Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, Li H. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle (Georgetown, Tex). 2019;18(14):1660–9.CrossRef Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, Li H. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle (Georgetown, Tex). 2019;18(14):1660–9.CrossRef
17.
go back to reference Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan J, Li R, Xi H, Fu W, et al. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6(17):14993–5007.CrossRef Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan J, Li R, Xi H, Fu W, et al. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6(17):14993–5007.CrossRef
18.
go back to reference Zeng J, Liu T, Zheng Y, Liu B, Fang M, Long S, Chen Y. Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells, vol. 10; 2017. Zeng J, Liu T, Zheng Y, Liu B, Fang M, Long S, Chen Y. Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells, vol. 10; 2017.
19.
go back to reference Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. Pharmacogn Rev. 2010;4(7):106–10.CrossRef Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. Pharmacogn Rev. 2010;4(7):106–10.CrossRef
20.
go back to reference Gao XY, Geng XJ, Zhai WL, Zhang XW, Wei Y, Hou GJ. Effect of combined treatment with cyclophosphamidum and allicin on neuroblastoma-bearing mice. Asian Pac J Trop Med. 2015;8(2):137–41.CrossRef Gao XY, Geng XJ, Zhai WL, Zhang XW, Wei Y, Hou GJ. Effect of combined treatment with cyclophosphamidum and allicin on neuroblastoma-bearing mice. Asian Pac J Trop Med. 2015;8(2):137–41.CrossRef
21.
go back to reference Wang CJ, Wang C, Han J, Wang YK, Tang L, Shen DW, Zhao Y, Xu RH, Zhang H. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer. Mol Biol Rep. 2013;40(12):6579–85.CrossRef Wang CJ, Wang C, Han J, Wang YK, Tang L, Shen DW, Zhao Y, Xu RH, Zhang H. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer. Mol Biol Rep. 2013;40(12):6579–85.CrossRef
22.
go back to reference Guo LH, Li H, Wang F, Yu J, He JS. The tumor suppressor roles of miR-433 and miR-127 in gastric Cancer. Int J Mol Sci. 2013;14(7):14171–84.CrossRef Guo LH, Li H, Wang F, Yu J, He JS. The tumor suppressor roles of miR-433 and miR-127 in gastric Cancer. Int J Mol Sci. 2013;14(7):14171–84.CrossRef
23.
go back to reference Fan J, Du W, Zhang H, Wang Y, Li K, Meng Y, Wang J. Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5. FEBS Lett. 2020;594(3):466–76.CrossRef Fan J, Du W, Zhang H, Wang Y, Li K, Meng Y, Wang J. Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5. FEBS Lett. 2020;594(3):466–76.CrossRef
25.
go back to reference Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.CrossRef Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.CrossRef
26.
go back to reference Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853–5.CrossRef Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853–5.CrossRef
27.
go back to reference Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21(43):6587–97.CrossRef Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21(43):6587–97.CrossRef
Metadata
Title
Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway
Authors
Wenfeng He
Yonghui Fu
Yongliang Zheng
Xiaoping Wang
Bin Liu
Junquan Zeng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07833-5

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine